Can a portable MRI see brain lesions as well as big machines?

NCT ID NCT07296263

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study looks at whether a portable MRI machine, combined with a standard contrast dye, can clearly show brain lesions like tumors or infections. About 85 adults with known or suspected brain lesions will get a scan before and after receiving the dye. The goal is to see if portable MRI can provide useful images, which could help patients who can't easily access traditional MRI scanners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gadolinium-based contrast agent
What this could lead to
If successful, this could make high-quality brain imaging more accessible using portable MRI machines, especially for patients who cannot use traditional scanners.
What could go wrong
This is an early-stage study focused on image quality, not treatment. The portable MRI has lower magnetic strength than standard machines, so it may not detect all lesions clearly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria To be eligible to participate in this study, an individual must meet all the following criteria: * Age ≥18 years Clinical indication of suspected or known brain lesion(s) with focal blood-brain barrier disruption. Preferably, at least one previously documented brain lesion with focal areas of blood-brain barrier disruption categorizable as: * intra-axial tumor(s) * extra-axial tumor(s) * infection/inflammatory lesion(s) * Cleared for portable MRI (pMRI) and intravenous GBCA administration per site policy. * Adequate peripheral venous access for contrast injection. * Able to provide informed consent and comply with brief supine imaging (pre- and post-contrast) Exclusion Criteria Participants will be excluded if they meet any of the following criteria: * Metallic clips or devices in the brain or eye. * Body weight greater than 200 kg. * Inability to fit or be positioned appropriately within the Swoop® Portable MR Imaging® System. * Inability to remain still or lie flat during the imaging period. * Not cleared for GBCA administration due to known hypersensitivity, allergy, or contraindication. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or acute kidney injury. * History of severe reaction to any gadolinium-based contrast agent. * GBCA administration within the prior 48 hours (or alternative clearance window defined by institution) * Known or suspected pregnancy at the time of imaging. * Any medical or behavioral condition that, in the investigator's judgment, would make participation unsafe or interfere with study completion. Subjects may be selectively enrolled or excluded to ensure inclusion of radiology finding subgroups and GBCA agents.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extra-axial tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRISTUS Trinity Mother Frances Health System

    Tyler, Texas, 75701, United States

  • Dent Neurologic Institute

    Amherst, New York, 14226, United States

  • Jefferson Abington Hospital

    Abington, Pennsylvania, 19001, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Neurology of Central Florida Research Center

    Altamonte Springs, Florida, 32714, United States

  • Texas Neurology

    Dallas, Texas, 75206, United States